| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-05-09 | ITCA 650 (exenatide, delivered continuously once or twice yearly through a matchstick-sized, subcutaneous osmotic mini-pump) | type 2 diabetes | 3 | Intarcia Therapeutics (USA - MA) | Metabolic diseases |
| 2016-05-09 | ConfirmMDx® for Prostate Cancer | prostate cancer | MDxHealth (Belgium) | Cancer - Oncology - Diagnostic | |
| 2016-05-09 | ulipristal acetate | uterine fibroids | 3 | Gedeon Richter (Hungary) Allergan (Ireland) | Gynecology - Women's health |
| 2016-05-06 | ARC-LPA | cardiovascular diseases | preclinical | Arrowhead Research Corporation (USA - CA) | Cardiovascular diseases |
| 2016-05-06 | ProSavin®/OXB-101 | Parkinson's disease | 1-2 | Oxford Biomedica (UK) | Neurodegenerative diseases |
| 2016-05-05 | glufosfamide | metastatic pancreatic adenocarcinoma | 3 | Eleison Pharmaceuticals (USA - FL) | Cancer - Oncology |
| 2016-05-05 | ozanimod (RPC1063) | moderate to severe ulcerative colitis | 2 | Celgene (USA - NJ) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2016-05-04 | elsiglutide (ZP1846) | prevention of chemotherapy-induced diarrhea in cancer patients | 2b | Zealand Pharma (Denmark) Helsinn (Switzerland) | Cancer - Oncology |
| 2016-05-04 | VXM01 | patients with metastatic colorectal cancer whose disease has progressed following one or two prior therapies | 2a | Vaximm (Germany) | Cancer - Oncology |
| 2016-05-04 | ISTH0036 - antisense oligonucleotide directed against TGF-ß2 mRNA | patients with advanced glaucoma undergoing filtration surgery (trabeculectomy) due to uncontrollable elevated intraocular pressure (IOP) | 1 | Isarna Therapeutics (Germany) | Ophtalmological diseases |
| 2016-05-04 | tildrakizumab (MK-3222) | psoriasis | 3 | Merck&Co (USA - NJ) Sun Pharmaceutical Industries (India) | Autoimmune diseases - Dermatological diseases - Inflammatory diseases |
| 2016-05-03 | citarinostat (ACY-241), ipilimumab and nivolumab | melanoma | 1b | Acetylon Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2016-05-03 | ALX-0171 | Respiratory Syncytial Virus (RSV) infection | 1-2a | Ablynx (Belgium) | Infectious diseases - Respiratory diseases |
| 2016-05-02 | Grafix® | acute and chronic wounds | Osiris Therapeutics (USA - MD) | ||
| 2016-05-02 | CGF166 | severe-to-profound bilateral hearing loss with intact vestibular function in the non-operative ear | 1-2 | Novartis (Switzerland) Genec (USA - MD) | Otorhinolaryngology |
| 2016-05-02 | fasinumab | moderate-to-severe osteoarthritis pain of the hip or knee | 2-3 | Regeneron Pharmaceuticals (USA - NY) | Rheumatic diseases - Inflammatory diseases |
| 2016-05-02 | sacituzumab govitecan - IMMU-132 | advanced, metastatic solid cancers | 2 | Immunomedics (USA - NJ) | Cancer - Oncology |
| 2016-05-02 | TB-403 | relapsed or refractory medulloblastoma | 1-2a | BioInvent (Sweden) Thrombogenics (Belgium) Oncurious (Belgium) Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) (USA - MI) | Cancer - Oncology |
| 2016-04-29 | galinpepimut-S (human Wilms tumor protein 1 peptides - WT1 vaccine) and nivolumab (Opdivo®) | ovarian cancer | 1 | SELLAS Life Sciences (Switzerland) | Cancer - Oncology |
| 2016-04-28 | fluorescent analog of RXI-109 | preclinical | RXi Pharmaceuticals (USA - MA) | Ophtalmological diseases - Dermatological diseases |
